AGIOS PHARMACEUTICALS, INC. (AGIO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Current obligations | 70.22M USD | Liabilities, Current |
| Cash and equivalents | 99.65M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 517.93M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | 35.75M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $70.22M | $99.65M | $517.93M | (m) | $35.75M | (m) |
| 2026-03-31 | (m) | $58.84M | $113.60M | $623.44M | (m) | $35.09M | (m) |
| 2025-12-31 | (m) | $82.21M | $89.13M | $765.29M | (m) | $32.92M | (m) |
| 2025-09-30 | (m) | $74.76M | $92.71M | $860.15M | (m) | $32.03M | (m) |
| 2025-06-30 | (m) | $70.41M | $80.87M | $858.07M | (m) | $30.85M | (m) |
| 2025-03-31 | (m) | $52.37M | $78.96M | $814.41M | (m) | $29.61M | (m) |
| 2024-12-31 | (m) | $81.16M | $76.25M | $817.46M | (m) | $27.62M | (m) |
| 2024-09-30 | (m) | $119.45M | $253.73M | $751.03M | (m) | $26.43M | (m) |
| 2024-06-30 | (m) | $62.64M | $84.52M | $485.37M | (m) | $23.94M | (m) |
| 2024-03-31 | (m) | $51.69M | $118.76M | $479.23M | (m) | $23.07M | (m) |
| 2023-12-31 | (m) | $67.95M | $88.20M | $688.72M | (m) | $19.08M | (m) |
| 2023-09-30 | (m) | $58.42M | $64.33M | $583.15M | (m) | $17.27M | (m) |
| 2023-06-30 | (m) | $55.14M | $84.75M | $617.81M | (m) | $15.67M | (m) |
| 2023-03-31 | (m) | $45.11M | $104.14M | $635.06M | (m) | $11.37M | (m) |
| 2022-12-31 | (m) | $62.63M | $139.26M | $643.86M | (m) | $8.49M | (m) |
| 2022-09-30 | (m) | $53.60M | $122.45M | $605.23M | (m) | $5.18M | (m) |
| 2022-06-30 | (m) | $48.40M | $88.54M | $730.77M | (m) | $4.06M | (m) |
| 2022-03-31 | (m) | $45.79M | $80.03M | $843.50M | (m) | $2.48M | (m) |
| 2021-12-31 | (m) | $59.83M | $203.13M | $816.89M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $57.90M | $400.22M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $60.65M | $969.12M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $96.50M | $1.89B | $447.58M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $94.39M | $127.44M | $445.49M | (m) | $14.70M | (m) |
| 2020-09-30 | (m) | $69.77M | $104.86M | $500.68M | (m) | $11.37M | (m) |
| 2020-06-30 | (m) | $64.35M | $295.86M | $494.27M | (m) | $11.23M | (m) |
| 2020-03-31 | (m) | $69.86M | $89.09M | $439.53M | (m) | $9.78M | (m) |
| 2019-12-31 | (m) | $92.89M | $80.93M | $483.95M | (m) | $7.33M | (m) |
| 2019-09-30 | (m) | $92.43M | $81.71M | $370.19M | (m) | $5.85M | (m) |
| 2019-06-30 | (m) | $89.50M | $83.58M | $411.81M | (m) | $4.66M | (m) |
| 2019-03-31 | (m) | $80.91M | $103.44M | $421.11M | (m) | $2.33M | (m) |
| 2018-12-31 | (m) | $93.50M | $70.50M | $514.80M | (m) | $869.00K | (m) |
| 2018-09-30 | (m) | $84.75M | $156.48M | $513.41M | (m) | $863.00K | (m) |
| 2018-06-30 | (m) | $84.87M | $210.32M | $506.58M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $74.70M | $364.47M | $417.98M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $94.94M | $102.72M | $321.21M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $88.11M | $132.74M | $375.19M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $93.65M | $138.72M | $447.32M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $82.43M | $200.28M | $279.48M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $88.43M | $160.75M | $380.56M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $78.00M | $285.50M | $293.60M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $67.26M | $234.05M | $231.32M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $45.05M | $39.03M | $273.86M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $52.89M | $71.76M | $245.24M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $49.76M | $80.05M | $272.32M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $45.20M | $72.53M | $297.26M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $36.38M | $35.26M | $309.45M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $61.09M | $14.03M | $328.03M | (m) | (m) | (m) |
| 2014-09-30 | (m) | $35.08M | $70.05M | $149.92M | (m) | (m) | (m) |
| 2014-06-30 | (m) | $44.64M | $108.25M | $130.23M | (m) | (m) | (m) |
| 2014-03-31 | (m) | $34.08M | $32.84M | $129.43M | (m) | (m) | (m) |
| 2013-12-31 | (m) | $36.93M | $71.56M | $95.21M | (m) | (m) | (m) |
| 2013-09-30 | (m) | $37.38M | $106.01M | $88.94M | (m) | (m) | (m) |
| 2013-06-30 | (m) | $36.98M | $77.48M | $21.79M | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $83.38M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $35.11M | $91.30M | $36.68M | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | $83.03M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $96.12M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $117.66M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $77.88M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |